Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.45 |
| ▸ | ADH1C | P00326 | 1/20 | 0.45 |
| ▸ | ADH1A | P07327 | 1/20 | 0.45 |
| ▸ | ADH4 | P08319 | 1/20 | 0.45 |
| ▸ | ADH7 | P40394 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 6/20 | 0.39 |
| ▸ | MMP1 | P03956 | 2/20 | 0.39 |
| ▸ | MMP8 | P22894 | 2/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15868930 | 0.98 | HTT (0.42) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL23029499 | 0.93 | ADH1B (0.41) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL172630 | 0.88 | — | — | |
| SCHEMBL11068082 | 0.84 | ADH1B (0.43) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL22080075 | 0.83 | ADH1B (0.42) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL13995749 | 0.83 | ADH1B (0.42) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL20394545 | 0.83 | ADH1B (0.42) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL1679102 | 0.83 | ADH1B (0.59) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL1679033 | 0.83 | ADH1B (0.59) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL1678544 | 0.83 | ADH1B (0.59) | ADH1BADH1CADH1AADH4ADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117264175-A | Polyisocyanate composition, aqueous coating composition, coated substrate, and method for producing polyisocyanate composition | 旭化成株式会社 | 2023-12-22 | — | — | CN | disclosed |
| CN-117229476-A | Polyisocyanate composition, blocked polyisocyanate composition, polyurethane resin composition, coating composition, and coated substrate | 旭化成株式会社 | 2023-12-15 | — | — | CN | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| CN-112996771-B | Polyisocyanate composition, coating composition and coated substrate | 旭化成株式会社 | 2023-08-01 | — | — | CN | disclosed |
| WO-2023104209-A1 | METTL3 INHIBITOR COMPOUND | 上海昂阔医药有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-11548870-B2 | Compounds useful as inhibitors of helios protein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-10 | — | — | US | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20210147383-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | BRISTOL-MYERS SQUIBB COMPANY | 2021-05-20 | — | — | US | disclosed |
| WO-2020247860-A1 | BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-12-10 | — | — | WO | disclosed |
| EP-1255738-B1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2012-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147383-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | IKZF2, RPL6, HNRNPR | ADH1B 3309/4885ADH1C 2600/4885ADH1A 3103/4885 |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | ADH1B 3475/4885ADH1C 3081/4885ADH1A 2969/4885 |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | ADH1B 3475/4885ADH1C 3081/4885ADH1A 2969/4885 |
| US-11548870-B2 | Compounds useful as inhibitors of helios protein | IKZF2, RPL6, HNRNPR | ADH1B 3309/4885ADH1C 2600/4885ADH1A 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.